Krystal Biotech (KRYS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.05
- Estimate
- $1.92
- Surprise
- +6.9%
- Revenue (period 2026-09-30)
- $127.3M
- Score today
- 6.2/10
Revenue source: xbrl.
How the report landed
Krystal Biotech (KRYS) beat the $1.92 estimate with adjusted EPS of $2.05 — a clear 6.9% upside surprise.
Coverage in the report window
- Krystal Biotech Delays Pipeline Data Releases to 2027 — fiscal.ai, 2026-11-02
Where TrendMatrix's rating stands now
TrendMatrix currently rates KRYS Buy (Wait) at 6.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +6.9% surprise compares with a +8.8% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: VYJUVEK
- Negative momentum
- Momentum score 3.0/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $295.90
- Entry target
- $281.66
- Price target
- $343.07
- Stop
- $272.96
- Upside to target
- +15.9%
- Reward-to-risk
- 1.9:1
The stock trades at 40.2× trailing but 32.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 3.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
KRYS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $8.76B
- P/E (fwd)
- 32.9
- P/E (ttm)
- 40.2
- 52-week range
- $184.02–$382.54
- Off 52-week high
- 22.6%
- RSI (14)
- 38
- Volume vs avg
- 3.90×
- Score today
- 6.2/10